Medicare Payment Relief For CAR-T Limited To Higher Add-On Payments In 2020
US Centers for Medicare and Medicaid Services concludes structural changes to existing payment systems to accommodate the high cost of Novartis’ Kymriah and Gilead’s Yescarta are still “premature.”
You may also be interested in...
CMS proposes new DRG with higher average payment rate for CAR-T therapy but signals new technology add-on payments will no longer be awarded to supplement reimbursement.
Peter Stein believes sponsors could have a role in “educating” the US FDA’s divisions and medical review staff about how registration trials can address payer data demands.
Eight inpatient prescription drugs are deemed eligible for supplemental payments in 2020, a big increase from years past, based on a review of US Medicare's new technology add-on payment approvals for prescription drugs since 2011.